Sponsor: Janssen
Sponsor Study ID: 64007957MMY3001
Study Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma
CTO #: 103428
NCT Number: NCT05083169
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Multiple Myeloma
Study Objectives: